Maria Kfoury

570 total citations
22 papers, 295 citations indexed

About

Maria Kfoury is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Reproductive Medicine. According to data from OpenAlex, Maria Kfoury has authored 22 papers receiving a total of 295 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Oncology, 8 papers in Pulmonary and Respiratory Medicine and 5 papers in Reproductive Medicine. Recurrent topics in Maria Kfoury's work include Cancer Immunotherapy and Biomarkers (9 papers), Ovarian cancer diagnosis and treatment (5 papers) and PARP inhibition in cancer therapy (5 papers). Maria Kfoury is often cited by papers focused on Cancer Immunotherapy and Biomarkers (9 papers), Ovarian cancer diagnosis and treatment (5 papers) and PARP inhibition in cancer therapy (5 papers). Maria Kfoury collaborates with scholars based in France, United Kingdom and Italy. Maria Kfoury's co-authors include Charles Naltet, Marie Boutet, Stéphanie Corgnac, Fathia Mami‐Chouaib, Benjamin Besse, Aurélien Marabelle, Christophe Massard, Stéphane Champiat, Jean‐Marie Michot and Salim Laghouati and has published in prestigious journals such as Clinical Cancer Research, International Journal of Molecular Sciences and Annals of Oncology.

In The Last Decade

Maria Kfoury

18 papers receiving 292 citations

Peers

Countries citing papers authored by Maria Kfoury

Since Specialization

Citations

This map shows the geographic impact of Maria Kfoury's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Maria Kfoury with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Maria Kfoury more than expected).

Fields of papers citing papers by Maria Kfoury

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Maria Kfoury. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Maria Kfoury. The network helps show where Maria Kfoury may publish in the future.

Co-authorship network of co-authors of Maria Kfoury

This figure shows the co-authorship network connecting the top 25 collaborators of Maria Kfoury. A scholar is included among the top collaborators of Maria Kfoury based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Maria Kfoury. Maria Kfoury is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Dynamic changes in TP53 mutated circulating tumor DNA predicts outcome of patients with high-grade ovarian carcinomas 2024 ·International Journal of Gynecological Cancer ·Maria Kfoury, Clément Bonnet, Nicolas Delanoy, Karen Howarth, Christophe Marzac, Étienne Rouleau, (unknown), Alexandra Léary	0
2	Deciphering Folate Receptor alphaGene Expression and mRNA Signatures in Ovarian Cancer: Implications for Precision Therapies 2024 ·International Journal of Molecular Sciences ·Maria Kfoury, Pascal Finetti, Émilie Mamessier, François Bertucci, Renaud Sabatier	0
3	The Use of Cyclin-Dependent Kinase 4/6 Inhibitors in Elderly Breast Cancer Patients: What Do We Know? 2024 ·Cancers ·(unknown), Renaud Sabatier, Frédérique Rousseau, Alexandre de Nonneville, Anthony Gonçalvès, (unknown), (unknown), F. Viret, (unknown), Maria Kfoury, (unknown), (unknown), (unknown)	2
4	Practical clinical management of ocular adverse events related to Antibody-Drug Conjugates in gynaecological malignancies 2024 ·Cancer Treatment Reviews ·(unknown), Frédérique Rousseau, (unknown), Renaud Sabatier, Maria Kfoury	0
5	Uterine adenosarcoma: Clinical significance of histological classification and SNP array analysis 2024 ·Human Pathology ·Carine Ngo, Sophie Cotteret, (unknown), Maria Kfoury, (unknown), Alicia Tran-Dien, (unknown), Alexandra Léary, Sébastien Gouy, Amandine Maulard, Philippe Morice, Jean‐Yves Scoazec, Patricia Pautier, Catherine Genestie	0
6	Evaluation of the satisfaction and experiences of oncology patients and doctors using teleconsultation during the COVID-19 pandemic 2024 ·Journal of Telemedicine and Telecare ·(unknown), Maryam Karimi, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Suzette Delaloge, Benjamin Besse, Maria Kfoury	2
7	Clinical Relevance of BRCA1 Promoter Methylation Testing in Patients with Ovarian Cancer 2023 ·Clinical Cancer Research ·Félix Blanc‐Durand, (unknown), (unknown), (unknown), Sophie Cotteret, Catherine Genestie, Audrey Le Formal, Patricia Pautier, Judith Michels, Maria Kfoury, (unknown), (unknown), (unknown), (unknown), (unknown), Jennifer Uzan, Étienne Rouleau, Alexandra Léary	18
8	Olaparib First-Line Maintenance Monotherapy in BRCA-Mutated Epithelial Ovarian Cancer: Descriptive Analysis of the First French Real-World Data Study 2023 ·Drugs - Real World Outcomes ·(unknown), Laurence Gladieff, Fanny Le Du, Dominique Berton, C. Bonnard, (unknown), (unknown), (unknown), (unknown), Gilles Freyer, Anne Floquet, (unknown), Maria Kfoury	2
9	PARP inhibitors (PARPi) prolongation after local therapy for oligo-metastatic progression in relapsed ovarian cancer patients 2023 ·Gynecologic Oncology ·(unknown), Maria Kfoury, Domenica Lorusso, Anne Floquet, Jole Ventriglia, (unknown), (unknown), Romain Rivoirard, (unknown), Laure Favier, Benoît You, Dominique Berton, Thibault De La Motte Rouge, Laura Mansi, Cyril Abdeddaim, (unknown), Laurence Lecomte, Magali Provansal, Cécile Dalban, I. L. Ray-Coquard	18
10	Career and Professional Development for Young Oncologists 2022 ·Oncology Research and Treatment ·Maximilian J. Mair, (unknown), Elizabeth A. Connolly, Maria Kfoury, Matteo Lambertini, Kok Haw Jonathan Lim, (unknown), Alexios Matikas, Rille Pihlak, Kevin Punie, Christoph Oing, Rodrigo Sánchez-Bayona, Paweł Sobczuk, Hongcheng Zhu, Anna S. Berghoff, Teresa Amaral	2
11	Analysis of the association between prospectively collected immune-related adverse events and survival in patients with solid tumor treated with immune-checkpoint blockers, taking into account immortal-time bias 2022 ·Cancer Treatment Reviews ·Maria Kfoury, (unknown), (unknown), Anne-Laure Voisin, Stéphane Champiat, Jean‐Marie Michot, Salim Laghouati, Caroline Robert, Benjamin Besse, Jean‐Charles Soria, Olivier Lambotte, Christophe Massard, Aurélien Marabelle, Matthieu Texier	35
12	528MO Is re-introduction or continuation of PARP inhibitors after local therapy for oligo-metastatic progression in patients with relapsed ovarian cancer relevant? 2022 ·Annals of Oncology ·(unknown), Maria Kfoury, Domenica Lorusso, Anne Floquet, Jole Ventriglia, (unknown), (unknown), Romain Rivoirard, (unknown), Laure Favier, Benoît You, Dominique Berton-Rigaud, Thibault De La Motte Rouge, Luigi Mansi, Cyril Abdeddaim, (unknown), Laurence Lecomte, (unknown), Cécile Dalban, Isabelle Laure Ray-Coquard	3
13	Impact de l’utilisation de la corticothérapie systémique sur l’efficacité des inhibiteurs de points de contrôle immunitaire 2021 ·Bulletin du Cancer ·(unknown), Maria Kfoury, Pernelle Lavaud, Aurélien Marabelle, Stéphane Champiat, Nawfel Mellas, Benjamin Besse, Christophe Massard, Arthur Géraud	1
14	ESMO20 YO for YO: highlights on metastatic renal cell carcinoma—the CheckMate-9ER trial 2021 ·ESMO Open ·Maria Kfoury, Christoph Oing	6
15	Multiple immune-related toxicities in cancer patients treated with anti-programmed cell death protein 1 immunotherapies: a new surrogate marker for clinical trials? 2021 ·Annals of Oncology ·Ariane Laparra, Maria Kfoury, Stéphane Champiat, (unknown), Patricia Martín-Romano, Audrey Simonaggio, Capucine Baldini, Perrine Vuagnat, Christine Mateus, Anne-Laure Voisin, Laurence Albigès, Benjamin Besse, Caroline Even, Caroline Robert, Salim Laghouati, Christophe Massard, Aurélien Marabelle, Olivier Lambotte, Jean‐Marie Michot	5
16	Impact of aging on immune-related adverse events generated by anti–programmed death (ligand)PD-(L)1 therapies 2020 ·European Journal of Cancer ·Capucine Baldini, P. Martin Romano, Anne-Laure Voisin, François‐Xavier Danlos, Stéphane Champiat, Salim Laghouati, Maria Kfoury, H. Vincent, Sophie Postel‐Vinay, Andreea Varga, Perrine Vuagnat, Vincent Ribrag, Laura Mezquita, Benjamin Besse, Antoine Hollebecque, Olivier Lambotte, Jean‐Marie Michot, Jean‐Charles Soria, Christophe Massard, Aurélien Marabelle	63
17	827P First real-life data on olaparib in 1st line (1stL) maintenance BRCA1/2 mutated epithelial ovarian cancer (EOC) in France: Descriptive analysis of 201 patients (pts) enrolled in the cohort temporary authorization for use (ATUc) 2020 ·Annals of Oncology ·(unknown), Laurence Gladieff, Fanny Le Du, (unknown), Dominique Berton-Rigaud, C. Bonnard, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Céline Gavoille, Gilles Freyer, Anne Floquet, (unknown), Maria Kfoury	1
18	Les limites des inhibiteurs de points de contrôle immunitaire et la gestion de leur toxicité 2019 ·médecine/sciences ·Marie Kostine, Aurélien Marabelle, Thierry Schaeverbeke, Maria Kfoury	2
19	Actualités autour des inhibiteurs de checkpoints immunitaires : enseignements issus du congrès ASCO 2017 et perspectives 2018 ·Bulletin du Cancer ·Maria Kfoury, (unknown), Cécile Vicier, Olivia Le Saux, Paul Gougis, Christophe Sajous, Stéphane Vignot	6
20	The Emerging Role of CD8+ Tissue Resident Memory T (TRM) Cells in Antitumor Immunity: A Unique Functional Contribution of the CD103 Integrin 2018 ·Frontiers in Immunology ·Stéphanie Corgnac, Marie Boutet, Maria Kfoury, Charles Naltet, Fathia Mami‐Chouaib	114

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact